04.09.2017 | DFP-Fortbildung | Ausgabe 1-4/2017
Mammakarzinom
- Zeitschrift:
- Wiener klinische Wochenschrift Education > Ausgabe 1-4/2017
Tipp
Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Anzeige
1.
IARC. Breast cancer: Estimated incidence, mortality & prevalence. 2012.
http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2. Zugegriffen: 15.08.2017
2.
3.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.
CrossRefPubMedPubMedCentral
4.
5.
6.
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34.
https://doi.org/10.1016/S0140-6736(13)60140-3.
CrossRefPubMedPubMedCentral
7.
8.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.
CrossRefPubMedPubMedCentral
9.
Onkologie AG. Empfehlungen gynäkologische Onkologie Kommission Mamma 2017. 2016.
http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/.
10.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.
CrossRefPubMedPubMedCentral
11.
Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
CrossRef
12.
13.
Cuzick J. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast. 2003;12(S1):47.
CrossRef
14.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.
CrossRefPubMedPubMedCentral
15.
Early Breast Cancer Trialists’ Collaborative G.. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001;
https://doi.org/10.1002/14651858.CD000486.
16.
17.
Lange CA, Yee D. Endocr Relat Cancer 2011;18:C19–24.
http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2
CrossRefPubMedPubMedCentral
18.
19.
Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.
CrossRef
20.
Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B‑31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc Am Soc Clin Oncol. 2007;25(18 suppl):512.
21.
22.
Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012;
https://doi.org/10.1155/2012/417673.
PubMedPubMedCentral
- Titel
- Mammakarzinom
- Autor:
-
Kathrin Strasser-Weippl
- Publikationsdatum
- 04.09.2017
- DOI
- https://doi.org/10.1007/s11812-017-0086-4
- Verlag
- Springer Vienna
- Zeitschrift
-
Wiener klinische Wochenschrift Education
Ausgabe 1-4/2017
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765